New British Spinout May Get Snapped Up by Allergan for $400M

KaNDy Therapeutics, a women’s health spinout helmed by Mary Kerr, is rumored to be in acquisition talks that value the company at $400M (€322M).

Details are sparse, but according to a report from Bloomberg, Stevenage-based KaNDy Therapeutics is supposedly in the late stages of a discussion with Allergan about a possible buyout. KaNDy, a recent spinout from Managing Director Mary Kerr‘s other company, NeRRe Therapeutics (which was spun out of GSK), is developing a neurokinin-based treatment for menopause and valued at $400M (€322M).

As Kerr explained to us at our London Meetup last fall, KaNDy is named for its asset’s target, the KNDy neuronal network, which plays a key role in menopausal thermal regulation. The candidate is not yet in the clinic, but Kerr expressed her confidence in its potential demonstrated in preclinical studies. Even though this drug is still in the early stages, women’s health has been attracting a lot of interest: For instance, this time last year, ObsEva went public in one of 2017’s largest Nasdaq biotech IPOs.


Image via pathdoc / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.